Accounts Receivable, after Allowance for Credit Loss, Current of BridgeBio Pharma, Inc. from 30 Jun 2021 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: BridgeBio Pharma, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Jun 2021 to 31 Dec 2025.
BridgeBio Pharma, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $139,444,000, a 2853% increase year-over-year.
Source SEC data: View on sec.gov

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

BridgeBio Pharma, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$139,444,000	+$134,722,000	+2853%	31 Dec 2025	10-K	24 Feb 2026	2025	FY
Q3 2025	$116,518,000			30 Sep 2025	10-Q	29 Oct 2025	2025	Q3
Q2 2025	$76,868,000			30 Jun 2025	10-Q	05 Aug 2025	2025	Q2
Q1 2025	$115,265,000			31 Mar 2025	10-Q	29 Apr 2025	2025	Q1
Q4 2024	$4,722,000	+$2,971,000	+170%	31 Dec 2024	10-K	24 Feb 2026	2025	FY
Q4 2023	$1,751,000			31 Dec 2023	10-K	20 Feb 2025	2024	FY
Q2 2021	$1,213,000			30 Jun 2021	10-Q	05 Aug 2021	2021	Q2

* An asterisk sign (*) next to the value indicates that the value is likely invalid.